Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

A4 Amyloid BetaExplore study findings

What Amyloid Beta Ratios in Blood Can Reveal Before a Scan Changes

2 numbered sourcesSource years 2026

Peptides are amino acids linked by peptide bonds. Their amounts can sometimes be measured in a fluid sample and used as clues about a biological process. The amyloid beta family includes Aβ42 and Aβ40, two products of the same precursor that differ in length. The ratio of those two forms in plasma is a measurement of circulating peptides. An amyloid PET scan, by contrast, measures a tracer signal associated with deposited amyloid in the brain. The two tests do not sample the same material. [1, 2]

Azadeh Feizpour and colleagues studied 507 adults who had no cognitive impairment at enrollment and had brain amyloid measurements below the study's positive PET threshold. They measured baseline plasma Aβ42/40 using mass spectrometry and followed participants with repeat scans. Among people in the lowest PET category, those with an abnormal plasma ratio were more likely to cross the study's positive PET threshold during follow-up. About 19 percent of participants with an abnormal plasma ratio and a negative baseline scan progressed to PET positivity. Accounting for age, sex, APOE ε4 status and baseline scan burden reduced the estimated association but did not remove it. [1]

A separate 2026 analysis by Rodrigo Cánovas and colleagues used two mass spectrometry assays across four cohorts. Its modeling placed the average plasma ratio change before clear scan positivity, with variation related to APOE ε4. The date or age estimated for a group should not be read as a clock for an individual. The result depends on the assay, thresholds and the population being modeled. [2]

These studies help explain why a positive blood result and a negative scan are not automatically contradictory. They can reflect a difference in what each method detects and when it detects it. They can also disagree for reasons other than biological timing. A person with an abnormal result does not necessarily develop a positive scan, symptoms or dementia. One possible research use is selecting people for confirmatory imaging in prevention studies; Feizpour's group modeled a reduction in the number of scans needed for a particular enrollment strategy. That is a question about study design, not a demonstration that blood testing itself prevents disease. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop A4 Amyloid Beta

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.